<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774512467404</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774512467404</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Maggie H</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512467404">a</xref>
<xref ref-type="aff" rid="aff2-1740774512467404">b</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Willan</surname><given-names>Andrew R</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512467404">a</xref>
<xref ref-type="aff" rid="aff2-1740774512467404">b</xref>
</contrib>
</contrib-group>
<aff id="aff1-1740774512467404"><label>a</label>Program in Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada</aff>
<aff id="aff2-1740774512467404"><label>b</label>Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada</aff>
<author-notes>
<corresp id="corresp1-1740774512467404">Andrew R Willan, Child Health Evaluative Sciences, SickKids Research Institute, 555 University Avenue, Toronto, ON M5G 1X8, Canada. Email: <email>andy@andywillan.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>1</issue>
<fpage>54</fpage>
<lpage>62</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774512467404">
<title>Background</title>
<p> Most often, sample size determinations for randomized clinical trials are based on frequentist approaches that depend on somewhat arbitrarily chosen factors, such as type I and II error probabilities and the smallest clinically important difference. As an alternative, many authors have proposed decision-theoretic (full Bayesian) approaches, often referred to as value of information methods that attempt to determine the sample size that maximizes the difference between the trial’s expected utility and its expected cost, referred to as the expected net gain. Taking an industry perspective, Willan proposes a solution in which the trial’s utility is the increase in expected profit. Furthermore, Willan and Kowgier, taking a societal perspective, show that multistage designs can increase expected net gain.</p>
</sec>
<sec id="section2-1740774512467404">
<title>Purpose</title>
<p> The purpose of this article is to determine the optimal sample size using value of information methods for industry-based, multistage adaptive randomized clinical trials, and to demonstrate the increase in expected net gain realized. At the end of each stage, the trial’s sponsor must decide between three actions: continue to the next stage, stop the trial and seek regulatory approval, or stop the trial and abandon the drug.</p>
</sec>
<sec id="section3-1740774512467404">
<title>Methods</title>
<p> A model for expected total profit is proposed that includes consideration of per-patient profit, disease incidence, time horizon, trial duration, market share, and the relationship between trial results and probability of regulatory approval. The proposed method is extended to include multistage designs with a solution provided for a two-stage design. An example is given.</p>
</sec>
<sec id="section4-1740774512467404">
<title>Results</title>
<p> Significant increases in the expected net gain are realized by using multistage designs.</p>
</sec>
<sec id="section5-1740774512467404">
<title>Limitations</title>
<p> The complexity of the solutions increases with the number of stages, although far simpler near-optimal solutions exist. The method relies on the central limit theorem, assuming that the sample size is sufficiently large so that the relevant statistics are normally distributed.</p>
</sec>
<sec id="section6-1740774512467404">
<title>Conclusion</title>
<p> From a value of information perspective, the use of multistage designs in industry trials leads to significant gains in the expected net gain.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774512467404" sec-type="intro">
<title>Introduction</title>
<p>Consider a randomized clinical trial (RCT) in which a new intervention is to be compared to the standard with the purpose of determining whether or not the new intervention should be adopted in place of the standard. Current sample size calculations for such trials are usually based on frequentist or classical methods and are designed to achieve a particular power curve. The power curve, which is the probability of rejecting the null hypothesis as a function of the true treatment difference, is designed to pass through the null hypothesis (usually, no treatment difference) at the type I error probability (also known as alpha or the level of the test) and through one minus the type II error probability (also known as the power) at the smallest clinically important difference (SCID). The type I error probability is most often set to 0.05, regardless of the cost of making such an error. Consequently, a trial that randomizes patients with age-related macular degeneration between two different wavelengths of laser coagulation (see Willan <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr1-1740774512467404">1</xref>]) has the same probability of falsely rejecting the null hypothesis as does a trial of cesarean section versus vaginal delivery for women presenting in the breech position (see Hannah <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr2-1740774512467404">2</xref>]). In the former, there is little or no cost for declaring one wavelength superior to another when they are equally effective. However, in the latter, declaring cesarean section superior, when it is equally as effective as vaginal delivery, carries substantial cost. Assigning the same probability to the two errors makes little sense, quite apart from the fact that the value of 0.05 is somewhat arbitrary in the first place. Also, somewhat arbitrary is the typical choice of 0.2 for the type II error probability, which means that there is a 20% chance that the effort and money invested in the trial will be wasted even if the treatment difference is clinically important. And again, it fails to reflect the cost of making the error. The choice of the SCID can be less arbitrary and can be estimated by polling clinicians and decision makers. However, in practice, it is often back-solved from the sample size equation after substituting in a sample size that primarily reflects feasibility and cost. Even if a reasonable estimate of the SCID is available, there is a range of values for the treatment difference that is less than the SCID for which the chance of rejecting the null hypothesis, and adopting the new intervention, is greater than 50%.</p>
<p>Following Grundy <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr3-1740774512467404">3</xref>] and Raiffa and Schlaifer [<xref ref-type="bibr" rid="bibr4-1740774512467404">4</xref>], many authors [<xref ref-type="bibr" rid="bibr5-1740774512467404">5</xref><xref ref-type="bibr" rid="bibr6-1740774512467404"/><xref ref-type="bibr" rid="bibr7-1740774512467404"/><xref ref-type="bibr" rid="bibr8-1740774512467404"/><xref ref-type="bibr" rid="bibr9-1740774512467404"/><xref ref-type="bibr" rid="bibr10-1740774512467404"/><xref ref-type="bibr" rid="bibr11-1740774512467404"/><xref ref-type="bibr" rid="bibr12-1740774512467404"/><xref ref-type="bibr" rid="bibr13-1740774512467404"/><xref ref-type="bibr" rid="bibr14-1740774512467404"/><xref ref-type="bibr" rid="bibr15-1740774512467404"/><xref ref-type="bibr" rid="bibr16-1740774512467404"/><xref ref-type="bibr" rid="bibr17-1740774512467404"/><xref ref-type="bibr" rid="bibr18-1740774512467404"/><xref ref-type="bibr" rid="bibr19-1740774512467404"/><xref ref-type="bibr" rid="bibr20-1740774512467404"/><xref ref-type="bibr" rid="bibr21-1740774512467404"/><xref ref-type="bibr" rid="bibr22-1740774512467404"/><xref ref-type="bibr" rid="bibr23-1740774512467404"/><xref ref-type="bibr" rid="bibr24-1740774512467404"/><xref ref-type="bibr" rid="bibr25-1740774512467404"/><xref ref-type="bibr" rid="bibr26-1740774512467404"/>–<xref ref-type="bibr" rid="bibr27-1740774512467404">27</xref>] have proposed value of information methods, which are based on a Bayesian decision theory, as an alternative to frequentist approaches. Aldcock [<xref ref-type="bibr" rid="bibr28-1740774512467404">28</xref>] and Pezeshk [<xref ref-type="bibr" rid="bibr29-1740774512467404">29</xref>] provide reviews. Using value of information methods, the trial sample size that maximizes the expected net gain can be determined, where the expected net gain is the difference between the expected value of the (sample) information provided by the trial and the trial’s expected total cost. If the maximum expected net gain is negative, the decision can be made based on current information, adopting the new intervention if, and only if, the expected incremental net benefit is positive. On the other hand, if the maximum expected net gain is positive, then a trial is worthwhile, with the optimal sample size being that which maximizes the expected net gain. The value of the trial information relates to the increase it affords with respect to some utility. From a societal perspective, the utility might be the reduction in opportunity loss, while from an industrial perspective, the utility might be an increase in profit or revenue.</p>
<p>Taking a societal perspective, where health-care costs are covered through public expenditure and trial research is funded by government or donation-based philanthropic agencies, Willan and Pinto [<xref ref-type="bibr" rid="bibr21-1740774512467404">21</xref>] provide a solution under restrictive assumptions. Subsequent articles [<xref ref-type="bibr" rid="bibr8-1740774512467404">8</xref><xref ref-type="bibr" rid="bibr9-1740774512467404"/><xref ref-type="bibr" rid="bibr10-1740774512467404"/>–<xref ref-type="bibr" rid="bibr11-1740774512467404">11</xref>,<xref ref-type="bibr" rid="bibr25-1740774512467404">25</xref>–<xref ref-type="bibr" rid="bibr26-1740774512467404">26</xref>] provide solutions with the assumptions relaxed. Willan and Kowgier [<xref ref-type="bibr" rid="bibr24-1740774512467404">24</xref>] provide a solution for multistage adaptive designs from a societal perspective.</p>
<p>Industry perspectives have also been taken. Gittins and Pezeshk [<xref ref-type="bibr" rid="bibr12-1740774512467404">12</xref><xref ref-type="bibr" rid="bibr13-1740774512467404"/>–<xref ref-type="bibr" rid="bibr14-1740774512467404">14</xref>], Kikuchi <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr18-1740774512467404">18</xref>], Pezeshk and Gittins [<xref ref-type="bibr" rid="bibr20-1740774512467404">20</xref>], and Pezeshk [<xref ref-type="bibr" rid="bibr29-1740774512467404">29</xref>] use a decision-theoretic approach to determine optimal sample size under the assumption that the number of patients receiving the new intervention is a function of the size of the observed treatment effect and the associated statistical significance. Willan [<xref ref-type="bibr" rid="bibr23-1740774512467404">23</xref>] provides a solution for optimal sample size from an industrial perspective in which the value of the information from a new trial relates to the expected increase in profit and considers the parameters profit per patient, disease incidence, time horizon, trial duration, market share, discount rate, and the relationship between the current evidence and the probability of regulatory approval.</p>
<p>The work presented here is an extension of the single-stage design given in the study by Willan [<xref ref-type="bibr" rid="bibr23-1740774512467404">23</xref>] and proposes a multistage, adaptive design based on expected value of information methods from an industry perspective. By industry perspective, we mean the consideration of performing another trial by the company that holds the patent for a new health-care intervention. The methods are given in the next section, followed by an example. A discussion is provided in the final section.</p>
</sec>
<sec id="section8-1740774512467404">
<title>The model</title>
<sec id="section9-1740774512467404">
<title>Single-stage design</title>
<p>Consider the comparison of a new patented health-care intervention (e.g., drug or devise), denoted <italic>T</italic>, with the standard intervention, denoted <italic>S</italic>, with respect to the mean of some effectiveness outcome. Let the current information regarding the difference (<italic>T</italic>−<italic>S</italic>) in effectiveness between these two interventions be characterized by a normal density function <inline-formula id="inline-formula1-1740774512467404">
<mml:math display="inline" id="math1-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>·</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> with mean <inline-formula id="inline-formula2-1740774512467404">
<mml:math display="inline" id="math2-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> and variance <inline-formula id="inline-formula3-1740774512467404">
<mml:math display="inline" id="math3-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>. From an industry perspective, the value of additional information relates to the increase in expected profit resulting from an increase in the probability of regulatory approval. One model [<xref ref-type="bibr" rid="bibr23-1740774512467404">23</xref>] for the expected profit based on the current information (EPCI<sub>0</sub>) can be formulated as <inline-formula id="inline-formula4-1740774512467404">
<mml:math display="inline" id="math4-1740774512467404">
<mml:mrow>
<mml:mtext>EPC</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>I</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>R</mml:mi>
<mml:mi>k</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, where <italic>R</italic> is the profit realized from treating one patient with <italic>T, k</italic> is the annual incidence of the condition under consideration, <italic>h</italic> is the time horizon, <italic>s</italic> is the market share, and <inline-formula id="inline-formula5-1740774512467404">
<mml:math display="inline" id="math5-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> is the probability of regulatory approval as a function of the strength of the evidence characterized by a standardized mean difference, <inline-formula id="inline-formula6-1740774512467404">
<mml:math display="inline" id="math6-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>, where <inline-formula id="inline-formula7-1740774512467404">
<mml:math display="inline" id="math7-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>. We assume that issues of safety have been addressed and the approval depends solely on effectiveness.</p>
<p>For <inline-formula id="inline-formula8-1740774512467404">
<mml:math display="inline" id="math8-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, we will adopt a ‘sloping-step’ functional form proposed in the study by Willan [<xref ref-type="bibr" rid="bibr23-1740774512467404">23</xref>], given by</p>
<p>
<disp-formula id="disp-formula1-1740774512467404">
<mml:math display="block" id="math9-1740774512467404">
<mml:mrow>
<mml:mtable align="right" width="80%">
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mtable align="left">
<mml:mtr>
<mml:mtd columnalign="center">
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:mtd>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:mo>:</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>≤</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="center" columnspan="1">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>γ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>γ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:mtd>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:mo>:</mml:mo>
<mml:mi>γ</mml:mi>
<mml:mo>&lt;</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>&lt;</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo>≠</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="center" columnspan="1">
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:mtd>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:mo>:</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>≥</mml:mo>
<mml:mi>β</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mtable align="left">
<mml:mtr>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:mo>min</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>max</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>γ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>γ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:mo>:</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:mi>I</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>≥</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mtd>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:mo>:</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1740774512467404" xlink:href="10.1177_1740774512467404-eq1.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula9-1740774512467404">
<mml:math display="inline" id="math10-1740774512467404">
<mml:mrow>
<mml:mi>I</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>·</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> is the indicator function. An illustration of <inline-formula id="inline-formula10-1740774512467404">
<mml:math display="inline" id="math11-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> is given in <xref ref-type="fig" rid="fig1-1740774512467404">Figure 1</xref>. The function <inline-formula id="inline-formula11-1740774512467404">
<mml:math display="inline" id="math12-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> is 0 for <inline-formula id="inline-formula12-1740774512467404">
<mml:math display="inline" id="math13-1740774512467404">
<mml:mrow>
<mml:mi>z</mml:mi>
<mml:mo>≤</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>, 1 for <inline-formula id="inline-formula13-1740774512467404">
<mml:math display="inline" id="math14-1740774512467404">
<mml:mrow>
<mml:mi>z</mml:mi>
<mml:mo>≥</mml:mo>
<mml:mi>β</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>, and linear for <inline-formula id="inline-formula14-1740774512467404">
<mml:math display="inline" id="math15-1740774512467404">
<mml:mrow>
<mml:mi>γ</mml:mi>
<mml:mo>≤</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>≤</mml:mo>
<mml:mi>β</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>. The value of <inline-formula id="inline-formula15-1740774512467404">
<mml:math display="inline" id="math16-1740774512467404">
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula16-1740774512467404">
<mml:math display="inline" id="math17-1740774512467404">
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> are referred to as the lower and upper thresholds, respectively. In a simple model, one could set both thresholds equal to 1.96 to yield the traditional two-sided level of significance of 0.05. In which case, <inline-formula id="inline-formula17-1740774512467404">
<mml:math display="inline" id="math18-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>I</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>z</mml:mi>
<mml:mo>≥</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>96</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
<fig id="fig1-1740774512467404" position="float">
<label>Figure 1.</label>
<caption>
<p>The probability regulatory approval as a function of z.</p>
</caption>
<graphic xlink:href="10.1177_1740774512467404-fig1.tif"/>
</fig>
<p>Consider a possible new trial with <italic>n</italic> patients per arm. Combining the data from the new trial with the prior information, the mean <inline-formula id="inline-formula18-1740774512467404">
<mml:math display="inline" id="math19-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> and variance <inline-formula id="inline-formula19-1740774512467404">
<mml:math display="inline" id="math20-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> for the posterior distribution are given by</p>
<p>
<disp-formula id="disp-formula2-1740774512467404">
<mml:math display="block" id="math21-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>n</mml:mi>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:mfrac>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-1740774512467404" xlink:href="10.1177_1740774512467404-eq2.tif"/>
</disp-formula>
</p>
<p>and</p>
<p>
<disp-formula id="disp-formula3-1740774512467404">
<mml:math display="block" id="math22-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:mfrac>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-1740774512467404" xlink:href="10.1177_1740774512467404-eq3.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula20-1740774512467404">
<mml:math display="inline" id="math23-1740774512467404">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math>
</inline-formula> is the estimator of the difference in mean effectiveness based on the data from the new trial and <inline-formula id="inline-formula21-1740774512467404">
<mml:math display="inline" id="math24-1740774512467404">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> is the sum over treatment arms of the between-patient variance of effectiveness. Assuming normality, or relying on the central limit theorem, <inline-formula id="inline-formula22-1740774512467404">
<mml:math display="inline" id="math25-1740774512467404">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
<mml:mo>~</mml:mo>
<mml:mtext>N</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo>/</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
<p>The expected value of sample information (EVSI) of the new trial is the amount by which the expected profit has increased and depends on the sample size <italic>n</italic>. That is, <inline-formula id="inline-formula23-1740774512467404">
<mml:math display="inline" id="math26-1740774512467404">
<mml:mrow>
<mml:mtext>EVSI</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>Rks</mml:mi>
<mml:mo stretchy="false">{</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>h</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>E</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>hg</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">}</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, where <inline-formula id="inline-formula24-1740774512467404">
<mml:math display="inline" id="math27-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>/</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msqrt>
<mml:mo>,</mml:mo>
<mml:mspace width="0.50em"/>
<mml:mi>t</mml:mi>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mi>τ</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> is the duration of the trial in years, where <inline-formula id="inline-formula25-1740774512467404">
<mml:math display="inline" id="math28-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>2</mml:mn>
<mml:mi>n</mml:mi>
<mml:mo>/</mml:mo>
<mml:mi>a</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> is the duration of accrual, <inline-formula id="inline-formula26-1740774512467404">
<mml:math display="inline" id="math29-1740774512467404">
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> is the annual accrual rate, and <inline-formula id="inline-formula27-1740774512467404">
<mml:math display="inline" id="math30-1740774512467404">
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> is the duration of time between the end of patient accrual and the decision regarding approval and will be referred to as the follow-up period.</p>
<p>The closed-form solution for expected probability function of regulatory approval <inline-formula id="inline-formula28-1740774512467404">
<mml:math display="inline" id="math31-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>E</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> can be found in Ref. [<xref ref-type="bibr" rid="bibr23-1740774512467404">23</xref>]. The total cost (TC) for the new trial is a combination of an overall fixed cost <inline-formula id="inline-formula29-1740774512467404">
<mml:math display="inline" id="math32-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, a per-patient variable cost <inline-formula id="inline-formula30-1740774512467404">
<mml:math display="inline" id="math33-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, and a cost of analysis <inline-formula id="inline-formula31-1740774512467404">
<mml:math display="inline" id="math34-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, and it is given by <inline-formula id="inline-formula32-1740774512467404">
<mml:math display="inline" id="math35-1740774512467404">
<mml:mrow>
<mml:mtext>TC</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mn>2</mml:mn>
<mml:mi>n</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>. The expected net gain (ENG), defined as <inline-formula id="inline-formula33-1740774512467404">
<mml:math display="inline" id="math36-1740774512467404">
<mml:mrow>
<mml:mtext>ENG</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mtext>EVSI</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mtext>TC</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, is the difference between the expected value of sample information and total cost and is maximized at <italic>n</italic><sup>*</sup>. If <inline-formula id="inline-formula34-1740774512467404">
<mml:math display="inline" id="math37-1740774512467404">
<mml:mrow>
<mml:mtext>ENG</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>≤</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>, that is, if <inline-formula id="inline-formula35-1740774512467404">
<mml:math display="inline" id="math38-1740774512467404">
<mml:mrow>
<mml:mtext>EVSI</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>≤</mml:mo>
<mml:mtext>TC</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, the optimal sample size is 0, and it is suboptimal for the company to conduct a further trial since the total cost of doing so exceeds the expected value of sample information for all sample sizes. On the other hand, if <inline-formula id="inline-formula36-1740774512467404">
<mml:math display="inline" id="math39-1740774512467404">
<mml:mrow>
<mml:mtext>ENG</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>n</mml:mi>
<mml:mo>*</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>&gt;</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>, the optimal sample size is <italic>n</italic><sup>*</sup>, and the new trial is worthwhile.</p>
</sec>
<sec id="section10-1740774512467404">
<title>Multistage adaptive design</title>
<p>As illustrated by Willan and Kowgier [<xref ref-type="bibr" rid="bibr24-1740774512467404">24</xref>] for societal perspective trials, gains in expected net benefit can be realized by adopting a multistage adaptive design. In a multistage design at the beginning of each stage, some fraction of the optimal sample size for a single-stage design is recruited. At the end of each stage, the evidence is updated and a new optimal sample size is determined, where again some fraction is recruited in the next stage. The fraction recruited can be optimized at the beginning of each stage with respect to expected net gain (the fraction of the planned last stage is 1). If the optimal sample size at the end of a stage is zero, the trial is terminated, and if the probability of approval at termination is nonzero, the optimal decision is to submit for approval, otherwise the intervention should be abandoned. The general solution for the expected value of information, expected net gain, and expected sample size for a design with <italic>J</italic> stages is given in the <xref ref-type="app" rid="app1-1740774512467404">Appendix</xref> (supplementary material). A specific solution for a two-stage design is given in the next section with an example to follow.</p>
</sec>
<sec id="section11-1740774512467404">
<title>The two-stage design</title>
<p>Let <inline-formula id="inline-formula37-1740774512467404">
<mml:math display="inline" id="math40-1740774512467404">
<mml:mrow>
<mml:mtext>EVS</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>I</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula38-1740774512467404">
<mml:math display="inline" id="math41-1740774512467404">
<mml:mrow>
<mml:mtext>ES</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>S</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula39-1740774512467404">
<mml:math display="inline" id="math42-1740774512467404">
<mml:mrow>
<mml:mtext>ET</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>C</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, and <inline-formula id="inline-formula40-1740774512467404">
<mml:math display="inline" id="math43-1740774512467404">
<mml:mrow>
<mml:mtext>EN</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>G</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> be the expected value of sample information, expected sample size per arm, expected total cost, and expected net gain of a two-stage design, respectively, where <inline-formula id="inline-formula41-1740774512467404">
<mml:math display="inline" id="math44-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> patients allocated to each arm in the <italic>j</italic>th stage (<italic>j</italic> = 1, 2), where <inline-formula id="inline-formula42-1740774512467404">
<mml:math display="inline" id="math45-1740774512467404">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>≤</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>≤</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula43-1740774512467404">
<mml:math display="inline" id="math46-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mtext>or</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>. <inline-formula id="inline-formula44-1740774512467404">
<mml:math display="inline" id="math47-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula> if, and only if, the optimal sample size at the beginning of the second stage is zero.</p>
<p>When <inline-formula id="inline-formula45-1740774512467404">
<mml:math display="inline" id="math48-1740774512467404">
<mml:mrow>
<mml:mi>β</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>, it can be shown that</p>
<p>
<disp-formula id="disp-formula4-1740774512467404">
<mml:math display="block" id="math49-1740774512467404">
<mml:mrow>
<mml:mtable align="right" width="80%">
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:mtext>EVS</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>I</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:mo>=</mml:mo>
<mml:mi>R</mml:mi>
<mml:mi>k</mml:mi>
<mml:mi>s</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
</mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>h</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
</mml:mrow>
<mml:munderover>
<mml:mo>∫</mml:mo>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>∞</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:munderover>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:munderover>
<mml:mo>∫</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mi>∞</mml:mi>
</mml:mrow>
</mml:munderover>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:mspace width="0.50em"/>
<mml:mspace width="0.50em"/>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mi>h</mml:mi>
<mml:mo>−</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:munderover>
<mml:mo>∫</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:munderover>
<mml:munderover>
<mml:mo>∫</mml:mo>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>∞</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>∞</mml:mi>
</mml:mrow>
</mml:munderover>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>h</mml:mi>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mrow>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-1740774512467404" xlink:href="10.1177_1740774512467404-eq4.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula46-1740774512467404">
<mml:math display="inline" id="math50-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>·</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> is the probability density function for a normal random variable with mean <inline-formula id="inline-formula47-1740774512467404">
<mml:math display="inline" id="math51-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> and variance <inline-formula id="inline-formula48-1740774512467404">
<mml:math display="inline" id="math52-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo>/</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>; <inline-formula id="inline-formula49-1740774512467404">
<mml:math display="inline" id="math53-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>·</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> is the probability density function for a normal random variable with mean <inline-formula id="inline-formula50-1740774512467404">
<mml:math display="inline" id="math54-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> and variance <inline-formula id="inline-formula51-1740774512467404">
<mml:math display="inline" id="math55-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo>/</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>; <inline-formula id="inline-formula52-1740774512467404">
<mml:math display="inline" id="math56-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">/</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula53-1740774512467404">
<mml:math display="inline" id="math57-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, and <inline-formula id="inline-formula54-1740774512467404">
<mml:math display="inline" id="math58-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> is the observed treatment effect for the <italic>j</italic>th stage, for <italic>j</italic> = 1, 2; and <inline-formula id="inline-formula55-1740774512467404">
<mml:math display="inline" id="math59-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>/</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>, for <italic>j</italic> = 0, 1, 2. The integration limits <inline-formula id="inline-formula56-1740774512467404">
<mml:math display="inline" id="math60-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula57-1740774512467404">
<mml:math display="inline" id="math61-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> are defined such that if <inline-formula id="inline-formula58-1740774512467404">
<mml:math display="inline" id="math62-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>≤</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mtext>or</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>≥</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>, then the optimal sample size for the second stage is zero. That is, the trial continues to the second stage if, and only if, <inline-formula id="inline-formula59-1740774512467404">
<mml:math display="inline" id="math63-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>&lt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>&lt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
<p>The probability of stopping after the first stage is <inline-formula id="inline-formula60-1740774512467404">
<mml:math display="inline" id="math64-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msubsup>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>. The expected sample size per arm is <inline-formula id="inline-formula61-1740774512467404">
<mml:math display="inline" id="math65-1740774512467404">
<mml:mrow>
<mml:mtext>ES</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>S</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo>/</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msubsup>
<mml:mo>max</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>−</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo>/</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>, and therefore the expected total cost is <inline-formula id="inline-formula62-1740774512467404">
<mml:math display="inline" id="math66-1740774512467404">
<mml:mrow>
<mml:mtext>ET</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>C</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>2</mml:mn>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msubsup>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>C</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>max</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>−</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>}</mml:mo>
</mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
<p>The expected net gain is</p>
<p>
<disp-formula id="disp-formula5-1740774512467404">
<mml:math display="block" id="math67-1740774512467404">
<mml:mrow>
<mml:mtext>EN</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>G</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mtext>EVS</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>I</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mtext>ET</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>C</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-1740774512467404" xlink:href="10.1177_1740774512467404-eq5.tif"/>
</disp-formula>
</p>
<p>Let <inline-formula id="inline-formula63-1740774512467404">
<mml:math display="inline" id="math68-1740774512467404">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> be that value of <inline-formula id="inline-formula64-1740774512467404">
<mml:math display="inline" id="math69-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> in the interval [0,1] that maximizes <inline-formula id="inline-formula65-1740774512467404">
<mml:math display="inline" id="math70-1740774512467404">
<mml:mrow>
<mml:mtext>EN</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>G</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>. Setting <inline-formula id="inline-formula66-1740774512467404">
<mml:math display="inline" id="math71-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula> is always expected to be suboptimal, since the resulting design is essentially single-stage, where the possibility of entering more after the first stage is eliminated even when it is optimal to do so. Optimizing <inline-formula id="inline-formula67-1740774512467404">
<mml:math display="inline" id="math72-1740774512467404">
<mml:mrow>
<mml:mtext>EN</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>G</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> with respect to <inline-formula id="inline-formula68-1740774512467404">
<mml:math display="inline" id="math73-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> is illustrated in the next section.</p>
</sec>
<sec id="section12-1740774512467404">
<title>An example</title>
<p>Using the data from an example given in the study by Willan [<xref ref-type="bibr" rid="bibr23-1740774512467404">23</xref>], suppose a small trial is conducted with 116 patients randomized to each arm. The outcome measure of interest is binary and there were 41 (35.34%) ‘successes’ on <italic>T</italic> and 33 (28.45%) on <italic>S</italic>. The estimated difference in the probability of success is <inline-formula id="inline-formula69-1740774512467404">
<mml:math display="inline" id="math74-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3534</mml:mn>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2845</mml:mn>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>06897</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula> with estimated variance <inline-formula id="inline-formula70-1740774512467404">
<mml:math display="inline" id="math75-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3534</mml:mn>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3534</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>116</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2845</mml:mn>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2845</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>116</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>003725</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>. The estimated between-patient variance summed across arms is <inline-formula id="inline-formula71-1740774512467404">
<mml:math display="inline" id="math76-1740774512467404">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>+</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3534</mml:mn>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3534</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2845</mml:mn>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2845</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>4321</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>. The z statistic <inline-formula id="inline-formula72-1740774512467404">
<mml:math display="inline" id="math77-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">/</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msqrt>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>06897</mml:mn>
<mml:mo stretchy="false">/</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>003725</mml:mn>
</mml:mrow>
</mml:msqrt>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>130</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>, and since <inline-formula id="inline-formula73-1740774512467404">
<mml:math display="inline" id="math78-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>&lt;</mml:mo>
<mml:mi>γ</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula74-1740774512467404">
<mml:math display="inline" id="math79-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> For the base case, let <italic>R</italic> = 100; <italic>C<sub>f</sub></italic> = 1,000,000; <italic>C<sub>A</sub></italic> = 20,000; <italic>C<sub>v</sub></italic> = 3200; <italic>h</italic> = 20; <italic>k</italic> = 50,000; <italic>a</italic> = 300; τ = 0.5; γ = 1.65; β = 1.96; and <italic>s</italic> = 0.4.</p>
<p>The optimal sample size per arm for a single-stage design is 335, corresponding to an expected net gain of CAD$17.3 million and total cost of CAD$3.34 million. For the two-stage design, the optimal proportion of the optimal sample size for the first stage is 0.56, so that the number of subjects per arm recruited for the first stage is <inline-formula id="inline-formula75-1740774512467404">
<mml:math display="inline" id="math80-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>56</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mo>×</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mn>335</mml:mn>
<mml:mo>=</mml:mo>
<mml:mn>189</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>. The probability of stopping at the end of the first stage is 0.55. The expected optimal sample size for the second stage is 356, which leads to the expected optimal sample size for two-stage design as <inline-formula id="inline-formula76-1740774512467404">
<mml:math display="inline" id="math81-1740774512467404">
<mml:mrow>
<mml:mtext>E</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo>/</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>+</mml:mo>
<mml:mo>max</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>−</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo>/</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msubsup>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>189</mml:mn>
<mml:mo>+</mml:mo>
<mml:mn>75</mml:mn>
<mml:mo>+</mml:mo>
<mml:mo>max</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>356</mml:mn>
<mml:mo>−</mml:mo>
<mml:mn>75</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mo>×</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>45</mml:mn>
<mml:mo>=</mml:mo>
<mml:mn>390</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>. The expected net gain of the optimal two-stage design is CAD$20.9 million.</p>
<p>
<xref ref-type="fig" rid="fig2-1740774512467404">Figure 2</xref> is a plot of the expected net gain as a function of the proportion of the optimal sample size entered in the first stage. As expected, the expected net gain for the two-stage design always exceeds that of the one-stage design. <xref ref-type="fig" rid="fig3-1740774512467404">Figures 3</xref> and <xref ref-type="fig" rid="fig4-1740774512467404">4</xref> are plots of the probability of stopping at the end of the first stage and the expected total sample size, respectively, as functions of the proportion of optimal sample size entered at the first stage.</p>
<fig id="fig2-1740774512467404" position="float">
<label>Figure 2.</label>
<caption>
<p>The expected net gain (ENG) as a function of the proportion of optimal sample size entered during the first stage <inline-formula id="inline-formula77-1740774512467404">
<mml:math display="inline" id="math82-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
</caption>
<graphic xlink:href="10.1177_1740774512467404-fig2.tif"/>
</fig>
<fig id="fig3-1740774512467404" position="float">
<label>Figure 3.</label>
<caption>
<p>The probability of stopping after stage 1 as a function of the proportion of optimal sample size entered during the first stage <inline-formula id="inline-formula78-1740774512467404">
<mml:math display="inline" id="math83-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
</caption>
<graphic xlink:href="10.1177_1740774512467404-fig3.tif"/>
</fig>
<fig id="fig4-1740774512467404" position="float">
<label>Figure 4.</label>
<caption>
<p>The expected sample size as a function of the proportion of optimal sample size entered during the first stage <inline-formula id="inline-formula79-1740774512467404">
<mml:math display="inline" id="math84-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
</caption>
<graphic xlink:href="10.1177_1740774512467404-fig4.tif"/>
</fig>
<p>To evaluate the two-stage design under various circumstances, a sensitivity analysis was performed by varying the value of the following parameters: lower threshold (γ), time horizon (<italic>h</italic>), follow-up period (τ), accrual rate (<italic>a</italic>), per-patient profit (<italic>R</italic>), incidence (<italic>k</italic>), and market share (<italic>s</italic>). <xref ref-type="table" rid="table1-1740774512467404">Table 1</xref> contains the results of the sensitivity analysis for lower threshold (Panel A), time horizon (Panel B), follow-up period (Panel C), and accrual rate (Panel D). Moving horizontally across a panel, the value of the corresponding parameter changes, while all remaining parameters are fixed at their base case values. In each panel, the following is given: the optimal sample size and optimum expected net gain for the single-stage design, and the optimal proportion <inline-formula id="inline-formula80-1740774512467404">
<mml:math display="inline" id="math85-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>, expected optimal sample size and optimum expected net gain for the two-stage design.</p>
<table-wrap id="table1-1740774512467404" position="float">
<label>Table 1.</label>
<caption>
<p>Optimal sample size and optimum expected net gain for single- and two-stage designs for various values of lower threshold (Panel A), time horizon (Panel B), follow-up time (Panel C), and accrual rate (Panel D)</p>
</caption>
<graphic alternate-form-of="table1-1740774512467404" xlink:href="10.1177_1740774512467404-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>A</td>
<td>Lower threshold (γ)</td>
<td>1.28</td>
<td>1.44</td>
<td>1.65<sup><xref ref-type="table-fn" rid="table-fn1-1740774512467404">a</xref></sup></td>
<td>1.8</td>
<td>1.95</td>
</tr>
<tr>
<td/>
<td>Single-stage optimum ENG (in CAD$)</td>
<td>18.8 million</td>
<td>18.1 million</td>
<td>17.3 million</td>
<td>16.7 million</td>
<td>16.2 million</td>
</tr>
<tr>
<td/>
<td>Optimal single-stage sample size</td>
<td>291</td>
<td>310</td>
<td>335</td>
<td>353</td>
<td>370</td>
</tr>
<tr>
<td/>
<td>Optimal proportion <inline-formula id="inline-formula81-1740774512467404">
<mml:math display="inline" id="math86-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>0.62</td>
<td>0.58</td>
<td>0.56</td>
<td>0.50</td>
<td>0.47</td>
</tr>
<tr>
<td/>
<td>Two-stage optimum ENG (in CAD$)</td>
<td>21.7 million</td>
<td>21.3 million</td>
<td>20.8 million</td>
<td>20.5 million</td>
<td>20.2 million</td>
</tr>
<tr>
<td/>
<td>Expected optimal sample size</td>
<td>369</td>
<td>373</td>
<td>390</td>
<td>415</td>
<td>423</td>
</tr>
<tr>
<td>B</td>
<td>Time horizon (<italic>h</italic>)</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20<sup><xref ref-type="table-fn" rid="table-fn1-1740774512467404">a</xref></sup></td>
<td>25</td>
</tr>
<tr>
<td/>
<td>Single-stage optimum ENG (in CAD$)</td>
<td>1.18 million</td>
<td>6.00 million</td>
<td>11.5 million</td>
<td>17.3 million</td>
<td>23.4 million</td>
</tr>
<tr>
<td/>
<td>Optimal single-stage sample size</td>
<td>119</td>
<td>205</td>
<td>274</td>
<td>335</td>
<td>391</td>
</tr>
<tr>
<td/>
<td>Optimal proportion <inline-formula id="inline-formula82-1740774512467404">
<mml:math display="inline" id="math87-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>0.43</td>
<td>0.49</td>
<td>0.46</td>
<td>0.56</td>
<td>0.50</td>
</tr>
<tr>
<td/>
<td>Two-stage optimum ENG (in CAD$)</td>
<td>2.25 million</td>
<td>7.85 million</td>
<td>14.1 million</td>
<td>20.8 million</td>
<td>27.9 million</td>
</tr>
<tr>
<td/>
<td>Expected optimal sample size</td>
<td>164</td>
<td>207</td>
<td>306</td>
<td>390</td>
<td>465</td>
</tr>
<tr>
<td>C</td>
<td>Follow-up period (τ)</td>
<td>0</td>
<td>0.5<sup><xref ref-type="table-fn" rid="table-fn1-1740774512467404">a</xref></sup></td>
<td>1</td>
<td>1.5</td>
<td>2</td>
</tr>
<tr>
<td/>
<td>Single-stage optimum ENG (in CAD$)</td>
<td>17.9 million</td>
<td>17.3 million</td>
<td>16.7 million</td>
<td>16.1 million</td>
<td>15.5 million</td>
</tr>
<tr>
<td/>
<td>Optimal single-stage sample size</td>
<td>341</td>
<td>335</td>
<td>330</td>
<td>324</td>
<td>318</td>
</tr>
<tr>
<td/>
<td>Optimal proportion <inline-formula id="inline-formula83-1740774512467404">
<mml:math display="inline" id="math88-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>0.57</td>
<td>0.56</td>
<td>0.47</td>
<td>0.32</td>
<td>0.23</td>
</tr>
<tr>
<td/>
<td>Two-stage optimum ENG (in CAD$)</td>
<td>21.6 million</td>
<td>20.8 million</td>
<td>20.2 million</td>
<td>19.6 million</td>
<td>19.1 million</td>
</tr>
<tr>
<td/>
<td>Expected optimal sample size</td>
<td>353</td>
<td>390</td>
<td>426</td>
<td>390</td>
<td>391</td>
</tr>
<tr>
<td>D</td>
<td>Accrual rate (<italic>a</italic>)</td>
<td>150</td>
<td>200</td>
<td>300<sup><xref ref-type="table-fn" rid="table-fn1-1740774512467404">a</xref></sup></td>
<td>400</td>
<td>600</td>
</tr>
<tr>
<td/>
<td>Single-stage optimum ENG (in CAD$)</td>
<td>15.2 million</td>
<td>16.1 million</td>
<td>17.3 million</td>
<td>18.0 million</td>
<td>18.9 million</td>
</tr>
<tr>
<td/>
<td>Optimal single-stage sample size</td>
<td>244</td>
<td>282</td>
<td>335</td>
<td>375</td>
<td>428</td>
</tr>
<tr>
<td/>
<td>Optimal proportion <inline-formula id="inline-formula84-1740774512467404">
<mml:math display="inline" id="math89-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>0.54</td>
<td>0.48</td>
<td>0.56</td>
<td>0.50</td>
<td>0.44</td>
</tr>
<tr>
<td/>
<td>Two-stage optimum ENG (in CAD$)</td>
<td>18.7 million</td>
<td>19.7 million</td>
<td>20.8 million</td>
<td>21.5 million</td>
<td>22.1 million</td>
</tr>
<tr>
<td/>
<td>Expected optimal sample size</td>
<td>257</td>
<td>304</td>
<td>390</td>
<td>436</td>
<td>485</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1740774512467404">
<label>a</label>
<p>Base case.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In every entry in <xref ref-type="table" rid="table1-1740774512467404">Table 1</xref>, the two-stage design has larger expected optimum net gain and larger expected optimal sample size. Illustrated in Panel A of <xref ref-type="table" rid="table1-1740774512467404">Table 1</xref> is that as the lower threshold of <inline-formula id="inline-formula85-1740774512467404">
<mml:math display="inline" id="math90-1740774512467404">
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>·</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> increases, the optimal sample size increases and optimum expected net gain decreases. As the threshold increases, the probability of approval is reduced, lowering the expected net gain and justifying larger sample sizes in an attempt to increase the probability of approval. In Panel B, longer time horizons justify larger optimal sample sizes since the potential profit increases, making approval more worthwhile and increasing the optimum expected net benefit. Results in Panel C reveal that as the follow-up period increases, the optimum expected net gain is reduced. This is because as the follow-up period increases, more of the time horizon and associated potential profit is lost. For the single-stage design, the optimal sample size is reduced as the length of the follow-up period increases, while for the two-stage design, the optimal sample size increases as the follow-up time increases from 0 to 1, but decreases from 1 to 2. From Panel D, as the accrual rate increases, so do the optimal sample size and the optimum expected net gain. Larger accrual rates imply that the trial will end sooner, increasing the potential profit, justifying a larger sample size and increasing expected net gain.</p>
<p>A sensitivity analysis with respect to profit per patient is given in <xref ref-type="table" rid="table2-1740774512467404">Table 2</xref>. As profit per patient increases, both the optimum expected net gain and optimal sample size increase. This results because as the profit per patient increases, the value of approval, and thereby the value of sample information, increases. Because of the symmetry in expected profit function, the same relative changes in incidence and market share result in the exact same sensitivity analysis as illustrated in <xref ref-type="table" rid="table2-1740774512467404">Table 2</xref>.</p>
<table-wrap id="table2-1740774512467404" position="float">
<label>Table 2.</label>
<caption>
<p>Optimal sample size and optimum expected net gain for single- and two-stage designs for various values of profit per patient</p>
</caption>
<graphic alternate-form-of="table2-1740774512467404" xlink:href="10.1177_1740774512467404-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Profit per patient (<italic>R</italic>)</td>
<td>50</td>
<td>75</td>
<td>100<sup><xref ref-type="table-fn" rid="table-fn2-1740774512467404">a</xref></sup></td>
<td>150</td>
<td>200</td>
</tr>
<tr>
<td>Single-stage optimum ENG (in CAD$)</td>
<td>7.29 million</td>
<td>12.4 million</td>
<td>17.3 million</td>
<td>27.9 million</td>
<td>38.4 million</td>
</tr>
<tr>
<td>Optimal single-stage sample size</td>
<td>267</td>
<td>308</td>
<td>335</td>
<td>368</td>
<td>387</td>
</tr>
<tr>
<td>Optimal proportion <inline-formula id="inline-formula86-1740774512467404">
<mml:math display="inline" id="math91-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>0.47</td>
<td>0.59</td>
<td>0.56</td>
<td>0.51</td>
<td>0.51</td>
</tr>
<tr>
<td>Two-stage optimum ENG (in CAD$)</td>
<td>8.84 million</td>
<td>14.8 million</td>
<td>20.8 million</td>
<td>33.1 million</td>
<td>45.4 million</td>
</tr>
<tr>
<td>Expected optimal sample size</td>
<td>288</td>
<td>367</td>
<td>390</td>
<td>414</td>
<td>431</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1740774512467404">
<label>a</label>
<p>Base case.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Determining the optimal proportion to enter in the first stage is highly computer intensive. It involves optimizing with respect to α<sub>1</sub> and <italic>n</italic> and using numerical integration and optimization for determining the limits <inline-formula id="inline-formula87-1740774512467404">
<mml:math display="inline" id="math92-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula88-1740774512467404">
<mml:math display="inline" id="math93-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>. Since the optimal proportions reported in <xref ref-type="table" rid="table1-1740774512467404">Tables 1</xref> and <xref ref-type="table" rid="table2-1740774512467404">2</xref>, with the exception of long follow-up times, are close to 0.5 and because we observed that the expected net gain curves are relatively flat near the optimum, we calculated the expected net gain and percent reduction from optimum when α<sub>1</sub> is set equal to 0.5 for the situations described in <xref ref-type="table" rid="table1-1740774512467404">Tables 1</xref> and <xref ref-type="table" rid="table2-1740774512467404">2</xref>. The results are presented in <xref ref-type="table" rid="table3-1740774512467404">Table 3</xref>. With the exception of a time horizon of 5 years and a follow-up period of 2 years, all reductions from optimum in expected net gain were less than 1%. Even the exceptions were only 3.55% and 1.4%, respectively. The implications, at least for this example, are that one can achieve near-optimal results by simply determining optimal sample size for a single-stage design and entering half that many in the first stage of a two-stage design, thus eliminating the need to determine the optimal proportion for a two-stage design. This robustness is tested further by determining the percent reduction from optimum when α<sub>1</sub> is set equal to 0.5 for varying degrees of the strength of evidence. This was done is two ways. In the first, illustrated in <xref ref-type="table" rid="table4-1740774512467404">Table 4</xref>, the sample size was set to 116 (as in the example), and the proportions of success in each arm were varied to yield a range of z statistics from 0.564 to 1.70. In the second, illustrated in <xref ref-type="table" rid="table5-1740774512467404">Table 5</xref>, the risk difference was fixed as close as possible to 0.0690 (as in the example), and the sample size per arm was varied to yield a range of z statistics from 0.861 to 1.86. The results in <xref ref-type="table" rid="table4-1740774512467404">Tables 4</xref> and <xref ref-type="table" rid="table5-1740774512467404">5</xref> illustrate a remarkable robustness, with the majority of situations having less than a 1% reduction in optimum expected net gain and the maximum being less than 4%.</p>
<table-wrap id="table3-1740774512467404" position="float">
<label>Table 3.</label>
<caption>
<p>Expected net gain (ENG) and the percent reduction from optimum for α<sub>1</sub> = 0.5 for various values of lower threshold (Panel A), time horizon (Panel B), follow-up period (Panel C), accrual rate (Panel D), and profit per patient (Panel E)</p>
</caption>
<graphic alternate-form-of="table3-1740774512467404" xlink:href="10.1177_1740774512467404-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<td>A</td>
<td>Lower threshold (γ)</td>
<td>1.28</td>
<td>1.44</td>
<td>1.65<sup><xref ref-type="table-fn" rid="table-fn3-1740774512467404">a</xref></sup></td>
<td>1.8</td>
<td>1.95</td>
</tr>
<tr>
<td/>
<td>ENG at α<sub>1</sub> = 0.5 (millions)</td>
<td>21.62</td>
<td>21.25</td>
<td>20.81</td>
<td>20.42</td>
<td>20.15</td>
</tr>
<tr>
<td/>
<td>% reduction in ENG for α<sub>1</sub> = 0.5</td>
<td>0.31</td>
<td>0.39</td>
<td>0.32</td>
<td>0.29</td>
<td>0.25</td>
</tr>
<tr>
<td>B</td>
<td>Time horizon (<italic>h</italic>)</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20<sup><xref ref-type="table-fn" rid="table-fn3-1740774512467404">a</xref></sup></td>
<td>25</td>
</tr>
<tr>
<td/>
<td>ENG at α<sub>1</sub> = 0.5 (millions)</td>
<td>2.17</td>
<td>7.84</td>
<td>14.10</td>
<td>20.81</td>
<td>27.87</td>
</tr>
<tr>
<td/>
<td>% reduction in ENG for α<sub>1</sub> = 0.5</td>
<td>3.55</td>
<td>0.13</td>
<td>0.28</td>
<td>0.32</td>
<td>0.04</td>
</tr>
<tr>
<td>C</td>
<td>Follow-up period (τ)</td>
<td>0</td>
<td>0.5<sup><xref ref-type="table-fn" rid="table-fn3-1740774512467404">a</xref></sup></td>
<td>1</td>
<td>1.5</td>
<td>2</td>
</tr>
<tr>
<td/>
<td>ENG at α<sub>1</sub> = 0.5 (millions)</td>
<td>21.54</td>
<td>20.81</td>
<td>20.14</td>
<td>19.48</td>
<td>18.83</td>
</tr>
<tr>
<td/>
<td>% reduction in ENG for α<sub>1</sub> = 0.5</td>
<td>0.37</td>
<td>0.32</td>
<td>0.15</td>
<td>0.51</td>
<td>1.41</td>
</tr>
<tr>
<td>D</td>
<td>Accrual rate (<italic>a</italic>)</td>
<td>150</td>
<td>200</td>
<td>300<sup><xref ref-type="table-fn" rid="table-fn3-1740774512467404">a</xref></sup></td>
<td>400</td>
<td>600</td>
</tr>
<tr>
<td/>
<td>ENG at α<sub>1</sub> = 0.5 (millions)</td>
<td>18.72</td>
<td>19.65</td>
<td>20.81</td>
<td>21.52</td>
<td>22.11</td>
</tr>
<tr>
<td/>
<td>% reduction in ENG for α<sub>1</sub> = 0.5</td>
<td>0.27</td>
<td>0.20</td>
<td>0.32</td>
<td>0.04</td>
<td>0.18</td>
</tr>
<tr>
<td>E</td>
<td>Profit per patient (<italic>R</italic>)</td>
<td>50</td>
<td>75</td>
<td>100<sup><xref ref-type="table-fn" rid="table-fn3-1740774512467404">a</xref></sup></td>
<td>150</td>
<td>200</td>
</tr>
<tr>
<td/>
<td>ENG at α<sub>1</sub> = 0.5 (millions)</td>
<td>8.84</td>
<td>14.77</td>
<td>20.81</td>
<td>33.10</td>
<td>45.37</td>
</tr>
<tr>
<td/>
<td>% reduction in ENG for α<sub>1</sub> = 0.5</td>
<td>0.04</td>
<td>0.12</td>
<td>0.32</td>
<td>0.06</td>
<td>0.04</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1740774512467404">
<label>a</label>
<p>Base case.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-1740774512467404" position="float">
<label>Table 4.</label>
<caption>
<p>Optimal proportion and percent reduction in ENG for α<sub>1</sub> = 0.5 for various strengths of evidence with sample size fixed at 116 per arm</p>
</caption>
<graphic alternate-form-of="table4-1740774512467404" xlink:href="10.1177_1740774512467404-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Number of success on <italic>T</italic></th>
<th align="left">Number of success on <italic>S</italic></th>
<th align="left">z<sub>0</sub></th>
<th align="left">Optimal proportion <inline-formula id="inline-formula89-1740774512467404">
<mml:math display="inline" id="math94-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">% reduction in ENG for α<sub>1</sub> = 0.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td>35</td>
<td>0.564</td>
<td>0.13</td>
<td>0.55</td>
</tr>
<tr>
<td>40</td>
<td>34</td>
<td>0.846</td>
<td>0.49</td>
<td>0.04</td>
</tr>
<tr>
<td>41<sup><xref ref-type="table-fn" rid="table-fn4-1740774512467404">a</xref></sup></td>
<td>33</td>
<td>1.13</td>
<td>0.56</td>
<td>0.32</td>
</tr>
<tr>
<td>42</td>
<td>32</td>
<td>1.41</td>
<td>0.34</td>
<td>2.24</td>
</tr>
<tr>
<td>43</td>
<td>31</td>
<td>1.70</td>
<td>0.14</td>
<td>2.18</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1740774512467404">
<label>a</label>
<p>Base case.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-1740774512467404" position="float">
<label>Table 5.</label>
<caption>
<p>Optimal proportion and percent reduction in ENG for α<sub>1</sub> = 0.5 for various strengths of evidence with risk difference fixed close to 0.0690</p>
</caption>
<graphic alternate-form-of="table5-1740774512467404" xlink:href="10.1177_1740774512467404-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Number of patients per arm</th>
<th align="left">Number of success on <italic>T</italic></th>
<th align="left">Number of success on <italic>S</italic></th>
<th align="left">Risk difference</th>
<th align="left">z<sub>0</sub></th>
<th align="left">Optimal proportion <inline-formula id="inline-formula90-1740774512467404">
<mml:math display="inline" id="math95-1740774512467404">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">% reduction in ENG for α<sub>1</sub> = 0.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>18</td>
<td>14</td>
<td>0.0800</td>
<td>0.861</td>
<td>0.52</td>
<td>0.43</td>
</tr>
<tr>
<td>100</td>
<td>35</td>
<td>28</td>
<td>0.0700</td>
<td>1.07</td>
<td>0.55</td>
<td>0.29</td>
</tr>
<tr>
<td>116<sup><xref ref-type="table-fn" rid="table-fn5-1740774512467404">a</xref></sup></td>
<td>41</td>
<td>33</td>
<td>0.0690</td>
<td>1.13</td>
<td>0.56</td>
<td>0.32</td>
</tr>
<tr>
<td>150</td>
<td>53</td>
<td>43</td>
<td>0.0667</td>
<td>1.24</td>
<td>0.55</td>
<td>0.44</td>
</tr>
<tr>
<td>200</td>
<td>71</td>
<td>57</td>
<td>0.0700</td>
<td>1.50</td>
<td>0.40</td>
<td>1.62</td>
</tr>
<tr>
<td>300</td>
<td>106</td>
<td>85</td>
<td>0.0700</td>
<td>1.85</td>
<td>0.22</td>
<td>3.88</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1740774512467404">
<label>a</label>
<p>Base case.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section13-1740774512467404" sec-type="discussion">
<title>Discussion</title>
<p>Value of information methods when applied to clinical trial design can be used to determine the sample size that maximizes the expected net gain, where the expected net gain is defined as the difference between the expected value of the information the trial provides and the trial costs. It differs from the traditional sample size calculations that rely on arbitrary values for type I and II error probabilities and the SCID. For industry-based trials, we have assumed that the value of information relates to the expected increase in the profit resulting from the increase in the probability of regulatory approval with the additional information. We propose consideration of multistage designs as a means of increasing expected net gain and provide a solution for the two-stage design. In the example, the use of the two-stage design increased expected net gain by 20.8% for the base case and between 15.4% and 90.0% in the sensitivity analyses.</p>
<p>Although the increase in expected net gain may justify the added complexity, the computer-intensive procedure for determining the optimal proportion of sample size entered at the first stage and searching for proper integral limits of the first stage should not be underestimated. When taking a societal perspective, Willan and Kowgier [<xref ref-type="bibr" rid="bibr24-1740774512467404">24</xref>] found that determining the proportion of optimal sample size entered in each stage for a multistage design is very computer intensive. We encountered similar issues when taking an industry perspective, which were compounded by the use of the regulatory approval function. For a two-stage design, an iterative numerical search for the optimal proportion of sample size is performed. For every iteration, a double numerical integration is required, where the limits <inline-formula id="inline-formula91-1740774512467404">
<mml:math display="inline" id="math96-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula92-1740774512467404">
<mml:math display="inline" id="math97-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>U</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> must be determined by an optimization procedure. As the number of stages increases, the complexity of the methods increases geometrically. However, as demonstrated in the ‘Example’ section, a near-optimal solution is to enter half the optimal sample size from a single-stage design in the first stage of a two-stage design, thus eliminating the need to determine the optimal proportion <inline-formula id="inline-formula93-1740774512467404">
<mml:math display="inline" id="math98-1740774512467404">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
<p>Value of information methods depend on a number of pre-specified parameters. While these parameters are not arbitrary, they may well be uncertain, and an examination of the robustness of the optimal solution is recommended, as illustrated in <xref ref-type="table" rid="table1-1740774512467404">Tables 1</xref> and <xref ref-type="table" rid="table2-1740774512467404">2</xref>. Other forms for the regulatory approval function may be considered. However, if a sensitivity analysis indicates robustness with respect to the lower threshold (γ), then changing the curvature of the approval function is unlikely to affect the optimal solution. We have assumed that the parameters are constants, which may not be the case. For example, it might be more realistic to assume that some parameters, such as market share and per-patient profit, increase with the observed treatment effect or statistical significance. Also, a nonzero discount rate may be more reasonable, although it would unlikely affect the optimal solution much, as demonstrated in the study by Willan and Pinto [<xref ref-type="bibr" rid="bibr21-1740774512467404">21</xref>].</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-1740774512467404">
<title>Appendix 1</title>
<sec id="section14-1740774512467404">
<title>Notation</title>
<p>
<inline-formula id="inline-formula94-1740774512467404">
<mml:math display="inline" id="math99-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> Current mean treatment effect</p>
<p>
<inline-formula id="inline-formula95-1740774512467404">
<mml:math display="inline" id="math100-1740774512467404">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> Current variance of treatment effect</p>
</sec>
</app>
</app-group>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>M.H.C. is supported through a studentship by the Ontario Student Opportunity Trust Fund – Hospital for Sick Children Foundation Student Scholarship Program. A.R.W. is funded through the Discovery Grant Program of the Natural Sciences and Engineering Research Council of Canada (grant number 44868-08).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774512467404">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Cruess</surname><given-names>AF</given-names></name>
<name><surname>Ballantyne</surname><given-names>M</given-names></name>
</person-group>.<article-title>Argon green vs krypton red laser photocoagulation of extrafoveal choroidal neovascular lesions: Three-year results in age-related macular generation</article-title>. <source>Can J Ophthalmol</source> <year>1996</year>; <volume>31</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr2-1740774512467404">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hannah</surname><given-names>ME</given-names></name>
<name><surname>Hannah</surname><given-names>WJ</given-names></name>
<name><surname>Hewson</surname><given-names>SH</given-names></name>
<etal/>
</person-group>. <article-title>Term breech trial: A multicentre international randomised controlled trial of planned caesarean section and planned vaginal birth for breech presentation at term</article-title>. <source>Lancet</source> <year>2000</year>; <volume>356</volume>(<issue>9239</issue>): <fpage>1375</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr3-1740774512467404">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grundy</surname><given-names>PM</given-names></name>
<name><surname>Healy</surname><given-names>MJR</given-names></name>
<name><surname>Rees</surname><given-names>DH</given-names></name>
</person-group>.<article-title>Economic choice of the amount of experimentation</article-title>. <source>J R Stat Soc Series B Stat Methodol</source> <year>1956</year>;<volume>18</volume>(<issue>1</issue>): <fpage>32</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr4-1740774512467404">
<label>4.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Raiffa</surname><given-names>H</given-names></name>
<name><surname>Schlaifer</surname><given-names>R</given-names></name>
</person-group>. <source>Applied Statistical Decision Theory</source>. <publisher-name>Graduate School of Business Administration, Harvard University</publisher-name>, <publisher-loc>Cambridge, MA</publisher-loc>, <year>1961</year>.</citation>
</ref>
<ref id="bibr5-1740774512467404">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Posnett</surname><given-names>J</given-names></name>
</person-group>. <article-title>An economic approach to clinical trial design and research priority setting</article-title>. <source>Health Econ</source> <year>1996</year>; <volume>5</volume>(<issue>6</issue>): <fpage>513</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr6-1740774512467404">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies</article-title>. <source>J Health Econ</source> <year>1999</year>; <volume>18</volume>(<issue>3</issue>): <fpage>341</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr7-1740774512467404">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Thompson</surname><given-names>KM</given-names></name>
</person-group>.<article-title>A dynamic programming approach to the efficient design of clinical trials</article-title>. <source>J Health Econ</source> <year>2001</year>; <volume>20</volume>(<issue>5</issue>): <fpage>797</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr8-1740774512467404">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckermann</surname><given-names>S</given-names></name>
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>.<article-title>Expected value of information and decision making in HTA</article-title>. <source>Health Econ</source> <year>2007</year>; <volume>16</volume>(<issue>2</issue>): <fpage>195</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr9-1740774512467404">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckermann</surname><given-names>S</given-names></name>
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>.<article-title>Time and expected value of sample information wait for no patient</article-title>. <source>Value Health</source> <year>2008</year>; <volume>11</volume>(<issue>3</issue>): <fpage>522</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr10-1740774512467404">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckermann</surname><given-names>S</given-names></name>
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>.<article-title>The option value of delay in health technology assessment</article-title>. <source>Med Decis Making</source> <year>2008</year>; <volume>28</volume>(<issue>3</issue>): <fpage>300</fpage>–<lpage>05</lpage>.</citation>
</ref>
<ref id="bibr11-1740774512467404">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckermann</surname><given-names>S</given-names></name>
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>.<article-title>Globally optimal trial design for local decision making</article-title>. <source>Health Econ</source> <year>2009</year>; <volume>18</volume>(<issue>2</issue>): <fpage>203</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr12-1740774512467404">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gittins</surname><given-names>J</given-names></name>
<name><surname>Pezeshk</surname><given-names>H</given-names></name>
</person-group>.<article-title>How large should a trial be?</article-title> <source>Statistician</source> <year>2000</year>; <volume>49</volume>(<issue>Part 2</issue>): <fpage>177</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr13-1740774512467404">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gittins</surname><given-names>J</given-names></name>
<name><surname>Pezeshk</surname><given-names>H</given-names></name>
</person-group>.<article-title>A behavioral Bayes method for determining the size of a clinical trial</article-title>. <source>Drug Inf J</source> <year>2000</year>; <volume>34</volume>(<issue>2</issue>): <fpage>355</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr14-1740774512467404">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gittins</surname><given-names>J</given-names></name>
<name><surname>Pezeshk</surname><given-names>H</given-names></name>
</person-group>.<article-title>A decision theoretic approach to sample size determination in clinical trials</article-title>. <source>J Biopharm Stat</source> <year>2002</year>; <volume>12</volume>(<issue>4</issue>): <fpage>535</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr15-1740774512467404">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halpern</surname><given-names>J</given-names></name>
<name><surname>Brown</surname><given-names>BW</given-names><suffix>Jr</suffix></name>
<name><surname>Hornberger</surname><given-names>J</given-names></name>
</person-group>.<article-title>The sample size for a clinical trial: A Bayesian-decision theoretic approach</article-title>. <source>Stat Med</source> <year>2001</year>; <volume>20</volume>(<issue>6</issue>): <fpage>841</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr16-1740774512467404">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hornberger</surname><given-names>JC</given-names></name>
<name><surname>Brown</surname><given-names>BW</given-names><suffix>Jr</suffix></name>
<name><surname>Halpern</surname><given-names>J</given-names></name>
</person-group>.<article-title>Designing a cost-effective clinical trial</article-title>. <source>Stat Med</source> <year>1995</year>;<volume>14</volume>(<issue>20</issue>): <fpage>2249</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr17-1740774512467404">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hornberger</surname><given-names>J</given-names></name>
<name><surname>Eghtesady</surname><given-names>P</given-names></name>
</person-group>.<article-title>The cost-benefit of a randomized trial to a health care organization</article-title>. <source>Control Clin Trials</source> <year>1998</year>; <volume>19</volume>(<issue>2</issue>): <fpage>198</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr18-1740774512467404">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kikuchi</surname><given-names>T</given-names></name>
<name><surname>Pezeshk</surname><given-names>H</given-names></name>
<name><surname>Gittins</surname><given-names>J</given-names></name>
</person-group>.<article-title>A Bayesian cost-benefit approach to the determination of sample size in clinical trials</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>(<issue>1</issue>): <fpage>68</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr19-1740774512467404">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindley</surname><given-names>DV</given-names></name>
</person-group>.<article-title>The choice of sample size</article-title>. <source>Statistician</source> <year>1997</year>; <volume>46</volume>(<issue>2</issue>): <fpage>129</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr20-1740774512467404">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pezeshk</surname><given-names>H</given-names></name>
<name><surname>Gittins</surname><given-names>J</given-names></name>
</person-group>.<article-title>A fully Bayesian approach to calculating sample sizes for clinical trials with binary response</article-title>. <source>Drug Inf J</source> <year>2002</year>; <volume>36</volume>(<issue>1</issue>): <fpage>143</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr21-1740774512467404">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Pinto</surname><given-names>EM</given-names></name>
</person-group>.<article-title>The expected value of information and optimal clinical trial design</article-title>. <source>Stat Med</source> <year>2005</year>; <volume>24</volume>(<issue>12</issue>): <fpage>1791</fpage>–<lpage>806</lpage> (Correction: <italic>Stat Med</italic> 2006; <bold>25</bold>(4): 720).</citation>
</ref>
<ref id="bibr22-1740774512467404">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>.<article-title>Clinical decision making and the expected value of information</article-title>. <source>Clin Trials</source> <year>2007</year>; <volume>4</volume>(<issue>3</issue>): <fpage>279</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr23-1740774512467404">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>.<article-title>Optimal sample size determinations from an industry perspective based on the expected value of information</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>(<issue>6</issue>): <fpage>587</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr24-1740774512467404">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Kowgier</surname><given-names>ME</given-names></name>
</person-group>.<article-title>Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>(<issue>4</issue>): <fpage>289</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr25-1740774512467404">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Eckermann</surname><given-names>S</given-names></name>
</person-group>.<article-title>Optimal clinical trial design using value of information methods with imperfect implementation</article-title>. <source>Health Econ</source> <year>2010</year>; <volume>19</volume>(<issue>5</issue>): <fpage>549</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr26-1740774512467404">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Eckermann</surname><given-names>S</given-names></name>
</person-group>.<article-title>Accounting for between-study variation in incremental net benefit in value of information methodology</article-title>. <source>Health Econ</source> <year>2012</year>; <volume>21</volume>(<issue>10</issue>): <fpage>1183</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr27-1740774512467404">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Goeree</surname><given-names>R</given-names></name>
<name><surname>Boutis</surname><given-names>K</given-names></name>
</person-group>.<article-title>Value of Information methods for planning and analyzing clinical studies optimize decision making and research planning</article-title>. <source>J Clin Epidemiol</source> <year>2012</year>; <volume>65</volume>(<issue>8</issue>): <fpage>870</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr28-1740774512467404">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aldcock</surname><given-names>CJ</given-names></name>
</person-group>.<article-title>Sample size determination: A review</article-title>. <source>Statistician</source> <year>1997</year>; <volume>46</volume>(<issue>2</issue>): <fpage>261</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr29-1740774512467404">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pezeshk</surname><given-names>H</given-names></name>
</person-group>.<article-title>Bayesian techniques for sample size determination in clinical trials: A short review</article-title>. <source>Stat Methods Med Res</source> <year>2003</year>; <volume>12</volume>(<issue>6</issue>): <fpage>489</fpage>–<lpage>504</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>